Moreover, a decrease in FADD has been associated with poor clinical outcomes, such as drug resistance, inferior survival, increased recurrence or metastasis in many tumor types, such as human non-small cell lung cancer [5], thyroid adenoma/adenocarcinoma [6] or acute myeloid leukemia [7]. This evidence concerns the gene FADD and acute myeloid leukemia.